Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CEL-SCI Co. stock logo
CVM
CEL-SCI
$9.45
+15.5%
$3.59
$1.98
$39.30
$50.28M0.3380,418 shs521,184 shs
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
$0.37
$0.36
$0.22
$3.09
$21.62M1.481.18 million shsN/A
LianBio stock logo
LIAN
LianBio
$0.05
$0.30
$0.27
$4.99
$5.87M0.231.04 million shs3 shs
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$2.49
+0.2%
$2.62
$1.87
$4.20
$21.37M1.0355,648 shs2,477 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CEL-SCI Co. stock logo
CVM
CEL-SCI
+15.53%+15.24%+275.00%+25.50%-72.25%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
0.00%0.00%-3.62%+4.29%-86.12%
LianBio stock logo
LIAN
LianBio
0.00%+8.92%-87.26%-73.75%-82.76%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
+0.20%-7.62%-8.97%+3.11%-22.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CEL-SCI Co. stock logo
CVM
CEL-SCI
1.1236 of 5 stars
0.02.00.00.03.91.70.6
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
2.6793 of 5 stars
3.05.00.00.00.01.70.6
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/AN/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
2.314 of 5 stars
3.54.00.00.00.60.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
2.00
Hold$3.39827.59% Upside
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
3.00
Buy$23.50845.67% Upside

Current Analyst Ratings Breakdown

Latest LIAN, CVM, LSTA, and ELEV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $32.00
6/10/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
6/10/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral
6/9/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/9/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/A$1.02 per shareN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$1M21.41N/AN/A$3.49 per share0.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%8/5/2025 (Estimated)
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$19.99M-$2.30N/AN/AN/AN/A-61.37%-53.35%8/7/2025 (Estimated)

Latest LIAN, CVM, LSTA, and ELEV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$0.64N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$0.26N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$0.20-$0.24-$0.04-$0.24N/AN/A
5/8/2025Q1 2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$0.53-$0.55-$0.02-$0.55N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
0.67
19.40
19.40
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/A
7.52
7.52

Institutional Ownership

CompanyInstitutional Ownership
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
83.70%
LianBio stock logo
LIAN
LianBio
74.85%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
8.94%

Insider Ownership

CompanyInsider Ownership
CEL-SCI Co. stock logo
CVM
CEL-SCI
9.93%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
8.10%
LianBio stock logo
LIAN
LianBio
7.59%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
435.32 million64.67 millionOptionable
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
4059.22 million54.43 millionOptionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
308.62 million7.79 millionNot Optionable

Recent News About These Companies

Lisata Therapeutics, Inc. (LSTA) - Yahoo Finance
Lisata and GATC to use AI for new opioid use disorder drug

New MarketBeat Followers Over Time

Media Sentiment Over Time

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$9.45 +1.27 (+15.53%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$9.29 -0.16 (-1.69%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Elevation Oncology stock logo

Elevation Oncology NASDAQ:ELEV

$0.36 0.00 (0.00%)
As of 07/23/2025

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.05 0.00 (0.00%)
As of 08/1/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Lisata Therapeutics stock logo

Lisata Therapeutics NASDAQ:LSTA

$2.48 +0.01 (+0.20%)
Closing price 08/1/2025 03:54 PM Eastern
Extended Trading
$2.50 +0.02 (+0.60%)
As of 08/1/2025 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.